A phase III, multicentre, randomised, double-blind, parallel-group, comparative efficacy and safety study of D961H (20 mg once daily) versus placebo for the prevention of gastric and/or duodenal ulcers associated with daily nonsteroidal anti-inflammatory drug (NSAID) use

Trial Profile

A phase III, multicentre, randomised, double-blind, parallel-group, comparative efficacy and safety study of D961H (20 mg once daily) versus placebo for the prevention of gastric and/or duodenal ulcers associated with daily nonsteroidal anti-inflammatory drug (NSAID) use

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications NSAID-induced ulcer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Oct 2011 Primary endpoint 'Kaplan-Meier-event-free-survival-rate' has been met according to results presented at the 19th United European Gastroenterology Week.
    • 26 Oct 2011 Results presented at the 19th United European Gastroenterology Week.
    • 10 May 2010 Actual patient number (343) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top